Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Compounding Oversight: What Price Safety?

Executive Summary

As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.

You may also be interested in...



FDA Panel Showdown Coming Over Epidural Steroid Injection Safety

Millions of epidural steroid injections are done off label for pain every year in America, but in some cases at the cost of paralysis, stroke or even death; FDA’s Anesthetic and Analgesic Drug Products Advisory Committee will consider labeling changes on Nov. 25.

Rx Response Planning Tweaks After Successful Efforts In Super Storm Sandy

HHS and other stakeholders largely praise the work of industry’s Rx Response as a single point of contact for the government and pharmaceutical industry to address pharmaceutical supply chain challenges during Super Storm Sandy.

CDER Compounding Oversight Challenge Forces Axelrad To Narrow Her Focus

The long-time head of CDER’s Office of Regulatory Policy will become senior advisor to center Director Janet Woodcock in charge of pharmacy compounding issues effective Jan. 6.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS054801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel